| |
| Trade Name | ADVIA CENTAUR HBC IGM READYPACK REAGENTS/QUALITY CONTROL MATERIALS |
| Classification Name | test, hepatitis b (b core, be antigen, be antibody, b core igm) |
| Generic Name | igm antibody to hepatitis b core antigen |
| Applicant | SIEMENS HEALTHCARE DIAGNOSTICS |
| PMA Number | P030040 |
| Supplement Number | S004 |
| Date Received | 03/09/2009 |
| Decision Date | 04/09/2009 |
| Product Code | |
| Advisory Committee |
Microbiology |
| Supplement Type | normal 180 day track no user fee |
| Supplement Reason | labeling change - trade name |
| Expedited Review Granted? | No |
| Combination Product |
No
|
Approval Order Statement Approval for adding advia centaur xp instrument to the intended use of the approved device advia centaur hbc igm assay. The device, as modified, will be marketed under the trade name advia centaur hbc igm assay and is indicated for: the advia centaur hbc igm assay is an in vitro diagnostic test for the qualitative determination of igm response to hepatitis b virus core antigen in human serum and plasma (edta or lithium or sodium heparinized) using the advia centaur and advia centaur xp systems. The assay uses recombinant hbc antigen. This assay may be used in combination with other hepatitis b virus (hbv) marker assays to define the clinical status of known hbv infected patients or can be combined with other hbv. Hav (hepatitis a virus), and hcv (hepatitis c virus) assays for the diagnosis of patients presenting symptoms of acute viral hepatitis. Assay performance characteristics have not been established for immunocompro-mised or immunosuppressed patients, cord blood, neonatal specimens, infants, or children. Assay performance characteristics have not been established when the advia centaur hbc igm assay is used in conjunction with other manufacturers' assays for specific hbv serological markers. |